glp 1 agonist exenatide PDB-101: Diabetes Mellitus: Diabetes Mellitus: undefined: Glucagon-like peptide-1 receptor activation maintains

INDICATIONS FOR NOVEL ANTIDIABETIC MEDICATIONS GLP-1RAs and dual GIP/GLP-1 receptor agonists are approved for two main indications: T2DM and obesity

The development of dependable biomarkers to estimate therapy response and enhance patient selection constitutes another substantial unmet need, since individual responses to GLP-1 treatments might differ markedly

The pharmacist can have a key role in educating patients and providers about the importance of regular diabetes follow-up, home glucose monitoring, frequent HbA1c testing, and why multiple medications are needed

You could possibly de-escalate and go to a smaller maintenance dose